BRAF and neoplasm: The importance of MAPK pathway upregulation and the high prevalence of the BRAFV600E mutation in melanoma patients in conjunction with preclinical data showing that BRAF blockade results in apoptosis and tumor control in preclinical models provided the rationale for investigating sorafenib in this trial.